Zhitong Finance App News, China Biopharmaceutical (01177.HK) issued an announcement. The results of a clinical study of the national Class 1 innovative drug TQ-A3334 (TLR7 agonist) independently developed by the Group's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), have been selected for the latest breakthrough summary (LBA) of the 2026 American Society for Liver Disease Research (AASLD) annual meeting (LBA), and will be announced in the form of an oral report; Chia Tai Tianqing and GlaxoSmithKline (GSK) strategic cooperation products Bepirovirsen (ASO) was selected for 2 oral presentations and 8 poster presentations (including 1 excellent poster).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.